ストックスクリーナーアプリを入手
17.25
1.71%
-0.30
前日終値:
$17.55
開ける：
$17.79
24時間の取引高:
460.16K
Relative Volume:
1.13
時価総額：
$6.16B
収益：
$5.21B
当期純損益:
$-211.00M
株価収益率:
-27.92
EPS:
-0.6179
ネットキャッシュフロー:
$861.30K
1週間 パフォーマンス:
-4.38%
1か月 パフォーマンス:
+2.25%
6か月 パフォーマンス:
-1.43%
1年 パフォーマンス:
+12.60%
1日の値動き範囲:
$17.01
$17.79
1週間の範囲:
$17.01
$18.20
52週間の値動き範囲:
$13.77
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Compare BLCO vs ISRG, BDX, ALC, RMD, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.25 | 6.16B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
369.15 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
177.85 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.03 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
218.27 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
32.53 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Neutral |
| 2025-05-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-03-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 開始されました | Raymond James | Outperform |
| 2024-05-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 開始されました | Stifel | Hold |
| 2023-10-03 | 再開されました | Evercore ISI | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 開始されました | Needham | Hold |
| 2022-12-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-12 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-06-24 | 開始されました | Evercore ISI | Outperform |
| 2022-06-06 | 開始されました | Citigroup | Buy |
| 2022-05-31 | 開始されました | Deutsche Bank | Hold |
| 2022-05-31 | 開始されました | Goldman | Neutral |
| 2022-05-31 | 開始されました | Guggenheim | Buy |
| 2022-05-31 | 開始されました | JP Morgan | Neutral |
| 2022-05-31 | 開始されました | Jefferies | Buy |
| 2022-05-31 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 開始されました | Wells Fargo | Overweight |
| 2022-05-11 | 開始されました | Cowen | Outperform |
すべてを表示
Bausch Lomb Corp (BLCO) 最新ニュース
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb receives CE Mark for SeeLyra laser - grafa.com
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser - Investing.com
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser By Investing.com - Investing.com India
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - eagletribune.com
Bausch + Lomb Appoints Rob Nadler as SVP, Business Development and Corporate Strategy - VisionMonday.com
The Technical Signals Behind (BLCO) That Institutions Follow - Stock Traders Daily
Leerink Partners Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
Bausch + Lomb Corporation (BLCO) Investor Outlook: Eyeing a 3.24% Upside Amid Diverse Global Operations - DirectorsTalk Interviews
Bausch + Lomb stock rises on survey-driven dry eye focus - AD HOC NEWS
Why Bausch + Lomb Corp stock is gaining today - Wealth Awesome
Bausch + Lomb study shows enVista Aspire lenses improve vision By Investing.com - Investing.com Canada
Bausch + Lomb study shows enVista Aspire lenses improve vision - Investing.com
Every patient in the study reached mid-range vision after cataract surgery. - Stock Titan
Does Advancing First-in-Class Dry Eye and Pain Drugs Change The Bull Case For Bausch + Lomb (BLCO)? - simplywall.st
Is Bausch + Lomb (TSX:BLCO) Strengthening Eye Care Leadership? - Kalkine Media
Bausch + Lomb Corporation - Menafn
Bausch + Lomb Survey Finds 14% Link Dry Eye to Menopause | BLCO Stock News - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing a 9.10% Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - finance.yahoo.com
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack - finance.yahoo.com
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - TradingView
Trading (BLCO) With Integrated Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine - Seeking Alpha
Did Bausch + Lomb’s (BLCO) Board Overhaul Amid Weak Returns Just Shift Its Investment Narrative? - simplywall.st
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 9.24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Director Robert J. Chersi Granted 11,776 RSUs Under 2022 Incentive Plan - Kalkine Media
Bausch & Lomb (BLCO) director Barbara Trebbi receives 11,776-share RSU award - Stock Titan
Bausch & Lomb (BLCO) files Form 3 for new director Barbara Trebbi - Stock Titan
Bausch & Lomb (BLCO) director awarded 11,776 RSU-based common shares - Stock Titan
Bausch & Lomb (BLCO) director receives 11,776 RSU equity grant as compensation - Stock Titan
Bausch & Lomb Corp (BLCO) adds director Robert J. Chersi in Form 3 filing - Stock Titan
Bausch & Lomb Corp (BLCO) director Thomas Appio reports holding 27,583 shares - Stock Titan
Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics? - Kalkine Media
Senior VP Of Bausch + Lomb Sold 54% Of Their Shares - Moomoo
Bausch + Lomb (NYSE:BLCO) CAO Sells 52,900 Shares - marketbeat.com
Bausch & Lomb (BLCO) SVP Frederick Munsch sells 52,900 shares in August trade - Stock Titan
Is Bausch + Lomb’s Raised 2026 Outlook And Board Refresh Altering The Investment Case For BLCO? - simplywall.st
Form 8K Bausch & Lomb Corp For: 12 August By Investing.com - Investing.com South Africa
Bausch & Lomb Corp (BLCO) Director Andrew C. von Eschenbach Sells 18,559 Shares - GuruFocus
BLCO (BLCO) shareholder plans NYSE sale of 52,900 restricted shares - Stock Titan
Bausch + Lomb (NYSE:BLCO) Director Eschenbach Andrew Von Sells 12,500 Shares - MarketBeat
Bausch & Lomb (NYSE: BLCO) director sells 18,559 shares after board exit - Stock Titan
Insider Selling: Bausch + Lomb (NYSE:BLCO) Director Sells $100,458.22 in Stock - MarketBeat
BLCO | Bausch + Lomb Corporation FinancialsIncome Statement - Quiver Quantitative
BLCO shareholder plans $887,885 stock sale (NYSE: BLCO) - Stock Titan
Bausch + Lomb Corporation (BLCO): Growth Potential and Analyst Ratings Point to an 11% Upside - DirectorsTalk Interviews
Bausch Lomb Corp (BLCO) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
0.07%
大文字化:
|
ボリューム (24 時間):